Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia.
A number of RXR modulators with novel structural features were synthesized and screened in the functional assays. The synthesis and the structure-activity relationship within the series of compounds will be presented. Some in vivo data generated in the models for dyslipidemia and diabetes will also be presented.
Lagu
Bharat
B
Johnson and Johnson Pharmaceutical Research and Development, Cranbury, NJ 08512, USA. bharat.lagu@novartis.com
Lebedev
Rimma
R
Pio
Barbara
B
Yang
Maria
M
Pelton
Patricia D
PD
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004195:Disease Models, Animal; D050171:Dyslipidemias / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D015363:Quinolones / Q000138:chemical synthesis / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D047488:Retinoid X Receptors / Q000819:agonists*; D013329:Structure-Activity Relationship
D007004:Hypoglycemic Agents; D015363:Quinolones; D047488:Retinoid X Receptors